When the ISS reaches its retirement date, the Axiom complex will detach and operate as a free-flying commercial space station.

This is the second contract SpaceX grabbed as it reached an agreement with Space Adventures on February 18 to launch private citizens on Crew Dragon spacecraft into an Earth orbit higher than ISS between late-2021 to mid-2022.

SpaceX will attempt to land the rocket booster back at Cape Canaveral, meaning residents in the area could hear a sonic boom. "This will be just the first of many missions to ISS to be completely crewed and managed by Axiom Space - a first for a commercial entity". In 2014, SpaceX and Boeing snagged a coveted launch contract collectively worth $6.8 billion to each build a spacecraft capable of transporting astronauts to the space station and back.

B1059 returned to Port Canaveral on December 7th, 2019 and will launch CRS-20 - its second Dragon mission - nearly exactly three months later. The flight's crew will live onboard the existing station for at least eight days.

When Dragon does return home, it will mark the end of SpaceX's original Commercial Resupply Services (CRS) contract with NASA. While this is not an issue for astronauts on board, as food from Earth is supplied regularly, for long-duration spaceflight-like those to the moon and Mars, which NASA is now planning-the issue of nutrition could become a problem.

Among the payloads on the Dragon is Bartolomeo, an external experiment platform developed by Airbus that will be installed on the station's Columbus module. The Earth views are supposed to be spectacular. Potential applications include Earth observation, robotics, material science and astrophysics. Studying these "tissue chips" may provide a better understanding on how they may cause disease on Earth.

Generation of Cardiomyocytes From Human Induced Pluripotent Stem Cell-derived Cardiac Progenitors Expanded in Microgravity (MVP Cell-03) examines whether microgravity increases the production of heart cells from human-induced pluripotent stem cells (hiPSCs).

"Since 2012, SpaceX has been delivering cargo to the International Space Station in partnership with NASA and later this year, we will fly NASA astronauts for the first time", said SpaceX President and Chief Operating Officer Gwynne Shotwell.

These are just a few of the hundreds of investigations providing opportunities for US government agencies, private industry, and academic and research institutions to conduct microgravity research that leads to new technologies, medical treatments and products that improve life on Earth.

Axiom Space is inviting individuals seeking out a trip of a lifetime.

A lot of the packaged food loses its nutritional value over time in Space, so it has been one of NASA's prime focuses to find products that can be grown on the ISS so as to provide astronauts with proper nutrition, as well as keeping their morale high.

Excerpt from:
SpaceX, Axiom to send three tourists to ISS in 2021 - ClickLancashire

Cardiac Stem Cells Comments Off on SpaceX, Axiom to send three tourists to ISS in 2021 – ClickLancashire | April 30th, 2020

In an unfortunate development, actor Rishi Kapoor lost his long battle with Leukemia. As we all know, the actor had travelled to the US for his treatment earlier and came back looking younger and healed. But he has had his share of health issues ever since. The family had been referring to the treatment as marrow and today the family confirmed that the actor was struggling with leukemia. Let us first understand what leukemia is - Leukemia is cancer of the body's blood-forming tissues, which includes the bone marrow as well as the lymphatic system. There are several types of leukemia, and some even affect the children, however, mostly leukemia occurs in adults. According to Cancer.org, most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells. . To understand the course of treatment that the actor may have undergone, we spoke exclusively to subject matter expert Dr Rahul Bhargava, Director, Haematology, Haemato - Oncology and Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram. The doctor says the way it appears, the star must have suffered from Acute myeloid leukemia (AML) which is a cancer that starts in the bone marrow, which is the soft inner part of certain bones, where the body makes new blood cells. This often quickly moves into the blood, as well. Talking about the treatment for this particular illness, Dr Bhargava said, There is a possibility that he underwent a MUD (Match unrelated donor) transplant with reduced intensity conditioning (RIC), which basically means that he was given a lower intensity treatment, considering his age. How does MUD work?In MUD, stem cells from outside are injected in the body, and mature stem cells are targeted and removed. A person has to be in the hospital for close to 21-25 days for this procedure and then we wait and see how the body responds to the treatment. The doctor adds that clearly the treatment couldnt control his disease and he succumbed to it.

See the article here:
Rishi Kapoor succumbs to Leukemia: Here is all we know about the condition and treatment - Times of India

Bone Marrow Stem Cells Comments Off on Rishi Kapoor succumbs to Leukemia: Here is all we know about the condition and treatment – Times of India | April 30th, 2020

BOCA RATON, Fla., April 29, 2020 /PRNewswire/ -- While most of the country has been on lockdown due to the coronavirus crisis, Gift of Life Marrow Registry donor Drake Jackson, traveled 1,000 miles to save the life of a stranger by donating his stem cells to a cancer patient in need of an urgent transplant. The 23-year-old was inspired by his hero and MLB professional baseball player Matt Szczur, who, in 2009 donated bone marrow to a young leukemia patient he had never met.

Jackson was an undergraduate at Illinois State University when he heard of Szczur's heroic act. "I'm a Chicago Cubs fan and when I found out that Matt [who played for the team at the time] had made this incredible donation to save a life, I felt that joining the registry was an easy thing to do to possibly help someone," said Jackson.

So, in November 2016, Jackson searched the internet and found Gift of Life Marrow Registry. He ordered a swab kit online and three years later he was called as a match for a patient battling leukemia.

Jackson was at work when Gift of Life's call came. Undaunted by the growing pandemic, he traveled to Florida in March from Illinois to the Dr. Miriam and Sheldon G. Adelson Gift of Life-Be The Match Collection Center to donate his lifesaving stem cells. "I encourage anyone to join the registry. It's super easy and everyone at Gift of Life is amazing, said Jackson."

After his procedure, Jackson connected with Szczur on social media and the two bonded over their experience as donors. So, when Jackson decided to shift his weddingoriginally planned for May in Key Westonline on April 22, Szczur's participation via video came as a special gift.

"I was honored to have been able to give a child a chance to live out her life when I donated bone marrow all those years ago," said Szczur. "To learn about the ripple effect of not only helping to save a life, but also inspiring Drake to do the same, is truly amazing. In these times of great difficulty, his story brings hope and a reminder that it takes just one person to make a difference."

To join the Gift of Life registry from home, potential donors can request a registration kit at giftoflife.org/register.

About Gift of Life Marrow RegistryGift of Life Marrow Registry is a 501(c)(3) nonprofit organization headquartered in Boca Raton, Fla. The organization, established in 1991, is dedicated to saving lives by facilitating bone marrow and blood stem cell transplants for patients with leukemia, lymphoma, and other blood-related diseases. To learn more about Gift of Life Marrow Registry, visit http://www.giftoflife.org.

Media contact: Edwige Buteau, Gift of Life Marrow RegistryOffice: +1 (516) 982-2921; Cell: +1 (917) 655-3843; [emailprotected]

SOURCE Gift of Life Marrow Registry

http://www.giftoflife.org

Go here to read the rest:
MLB Player Inspired Baseball Fan To Save Life Of Leukemia Patient During Pandemic - PRNewswire

Bone Marrow Stem Cells Comments Off on MLB Player Inspired Baseball Fan To Save Life Of Leukemia Patient During Pandemic – PRNewswire | April 30th, 2020

Doctors are hoping stem cell therapy could be a weapon in the fight against coronavirus. On Friday, regenerative medicine company Mesoblast announced a 300-person trial to determine whether stem cell treatments will work in COVID-19 patients suffering from severe lung inflammation.

One hospital in New York tried it as an experiment with 12 patients, 10 of whom were able to come off of ventilators.

"What we saw in the very first patient was that within four hours of getting the cells, a lot of her parameters started to get better," Dr. Karen Osman, who led the team at Mount Sinai, told CBS News' Adriana Diaz.

The doctor said she was encouraged by the results, though she was hesitant to link the stem cell procedure to her patients' recovery.

"We don't know" if the 10 people removed from ventilators would not have gotten had they not gotten the stem cells, she said. "And we would never dare to claim that it was related to the cells."

She explained that only a "randomized controlled trial" would be the only way "to make a true comparison."

Luis Naranjo, a 60-year-old COVID-19 survivor, was one of Mount Sinai's stem cell trial success stories. He told Diaz in Spanish that he was feeling "much better."

Naranjo's daughter, Paola, brought him to the emergency room, fearful she would not see her father again. Like so many families struck by the coronavirus, she was not allowed inside with him.

"I forgot to tell him that I love him," she said. "All I said was go inside, I hope you feel better."

During his hospital stay, Naranjo was unconscious and on a ventilator for 14 days.

Doctors proposed giving him stem cells from bone marrow in hopes it would suppress the severe lung inflammation caused by the virus.

Now, Naranjo credits the doctors who treated him for his survival. Though income from his family's jewelry business has been cut off and they found themselves falling behind on rent, Naranjo said he is focused primarily on his recovery and regaining the 25 pounds he lost at the hospital.

Although stem cell treatment, usually reserved for other diseases like rheumatoid arthritis, might end up being another step toward helping coronavirus patients recover, Dr. Osman was quick to say it would not be a "miracle treatment."

"The miracle treatment will be a vaccine," she said.

Read more:
Doctors experiment with unproven stem cell therapy on COVID-19 patients - CBS News

Bone Marrow Stem Cells Comments Off on Doctors experiment with unproven stem cell therapy on COVID-19 patients – CBS News | April 30th, 2020

- Advertisement -

Doctors treating severe COVID-19 instances in New York attempted stem cell treatment on 12 patients, 10 of whom came off ventilators after receiving treatment.

It is uncertain whether the publication coronavirus disease could be treated with stem cells, but scientists in Mesoblast are going to conduct a clinical trial on 300 serious patients to find more replies.

Anecdotal evidence suggests that stem cells can be helpful, however, the science behind it has to be clarified. The book coronavirus might not have a remedy right now, but it is still worth noting the huge research effort which goes into discovering treatments that could restrict COVID-19 complications and prevent death.

Doctors have observed the positive effects of a garden range of drugs that are supposed to treat other disorders, and some of these medicines are contained in enormous trials across the world. Scientists are also working on over 70 vaccine applicants for COVID-19, using some of them showing promising results. In addition to that, theres plasma from predators that is rich in antibodies which may help individuals with weaker immune systems.

And doctors think they have found another promising remedy for COVID-19: Stem cells. You frequently hear about stem cells and these reports are often miraculous. Stem cells are human cells which have thesuperpower to change into just about any cell of their human body and they can be used to treat some health problems. Stem cells can regenerate lung tissue, fight inflammation, and help acute COVID-19 patients breathe on their own back.

Doctors at Mount Sinai treated 12 patients with stem cell treatment, and 10 of these came off their ventilators soon after, CBSNews reports. The doctors themselves have no idea what helped the patients improve, and cant definitively say that its the stem cells that stored their patients.

What we saw in the very first patient was that within four hours of getting the cells, a lot of her parameters started to get better, Dr. Karen Osman advised CBS. The doctor made it clear they cant claim the stem cell treatments are what saved the sufferers. We dont know, she said. And wed never dare to assert that it had been associated with the cells.

The doctor explained that just a randomized controlled trial would have the ability to inform them whether the stem cells can assist with the recovery of COVID-19 patients. Thankfully, one particular study is going to get underway. Mesoblast will trial stem cell treatments on 300 patients suffering from severe lung inflammation. Osman and her staff think that stem cells extracted from bone marrow could suppress the inflammation in COVID-19 patients, and that is why they tried the treatment. Naranjo has recovered following stem cell treatment, and hes at home focusing on regaining his strength.

The miracle treatment is going to be a vaccine. While we await any Type of effective COVID-19 treatment, heres a simple explainer for stem cells:

- Advertisement -

Follow this link:
New York Is Going To Conduct Stem Cell Treatment For COVID-19 Patients - World Top Trend

Bone Marrow Stem Cells Comments Off on New York Is Going To Conduct Stem Cell Treatment For COVID-19 Patients – World Top Trend | April 30th, 2020

Thefirst-in-human, universal chimeric receptor antigen (CAR) T-cell (CAR-T)therapy GC027 was tolerable and resulted in antileukemic responses amongpatients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL),according to results from a phase 1 trial presented at the American Associationfor Cancer Research (AACR) Virtual Annual Meeting I 2020.1

Theuniversal CAR T cells target CD7, which, according to Xinxin Wang, PhD, ofGracell Biotechnologies Co, Ltd, in China, and lead author and presenter of thestudy, is a good target for T-ALL because it is expressed by more than 95% ofT-ALL patients.

GC027 isallogeneic, which may prevent the development of graft-versus-host disease. Theproduct is introduced using lentivirus for rapid elimination of T-ALL cells. Preclinicalstudies showed efficacy in a T-ALL xenograft model, and this prospective studyevaluated the safety and efficacy in humans.

Thesingle-arm, open-label study treated 5 adult patients with relapsed/refractoryCD7-positive T-ALL with a single infusion of 1 of 3 different dose levels ofG027: 0.6 x 107/kg, 3 x 107/kg, and 1.5 x 107/kg.Lymphodepletion therapy was administered prior to the G027 infusion. Theprimary endpoint was safety and the secondary endpoints included objectiveresponse rate (ORR) within 3 months after G027 infusion.

Patientswith extramedullary or central nervous system disease were excluded. Atbaseline, the median age was 24 (range, 19-38). Patients were heavilypretreated, with 5 median number of prior therapies (range, 1-9). Two patientshad high-risk disease and the median bone marrow tumor burden was a median of38.2% of blasts. None of the patients had undergone a prior allogeneic hematopoieticstem cell transplant.

Allpatients developed cytokine release syndrome (CRS), 4 of which were grade 3 and1 was grade 4. All cases were manageable and resolved with treatment andsupportive care. None of the patients developed neurotoxicity.

The completeremission (CR)/CR with incomplete hematologic recovery was 100%. By day 28, 4patients achieved a CR with negative for minimal residual disease (MRD) and 3of these patients remained MRD negative up to day 161. One patient achieved CRbut was MRD positive, and relapsed by day 29.

Peak CART-cell expansion in peripheral blood occurred between week 1 and 2.

As the first-in-human, universal CAR T-cell therapy for adult relapsed/refractory T-ALL, Dr Wang said, GC027 has demonstrated superior clinical efficacy and induced deep response in patients with acceptable safety profile. She added that trial enrollment is ongoing.

Read more of Cancer Therapy Advisors coverage of AACR 2020 meeting by visiting the conference page.

Reference

Wang X, Li S, Gao L, et al. Clinical safety and efficacy study of TruUCAR GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). Presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting I; April 27-28, 2020. Abstract CT052.

Here is the original post:
First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL - Cancer Therapy Advisor

Bone Marrow Stem Cells Comments Off on First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL – Cancer Therapy Advisor | April 30th, 2020

A novel,bispecific CD19/CD22 chimeric antigen receptor T-cell (CAR-T) therapy wastolerable and resulted in responses among patients with acute lymphoblasticleukemia (ALL), according to results from a phase 1 trial presented at the AmericanAssociation for Cancer Research (AACR) Virtual Annual Meeting I 2020.

Thenovel CAR-T therapy was developed with the hypothesis that dual antigen-targetingstrategies may prevent antigen negative escape, Haneen Shalabi, DO, of theNational Cancer Institute and lead author and presenter of the study, said.

Thephase 1, dose-escalation study treated 13 young patients with ALL with theCD19/CD22 CAR-T therapy at 3 different dose levels, including 3 x 105,1 x 106, and 3 x 106. The bispecific construct containedFMC63 (CD19 scFv) linked with m971 (CD22 scFv) and a 4-1 BB costimulatorydomain.

Patientsunderwent lymphodepletion with fludarabine plus cyclophosphamide prior to theirCAR-T infusion. The primary endpoints were safety and toxicity, and thesecondary endpoints were efficacy, chimeric antigen receptor (CAR) expansion,and CAR persistence.

Atbaseline, the median age was 19.6 (range, 5.4-28.5). Patients had receivedprevious treatments, including hematopoietic stem cell transplant (54%),CD19-targeted therapy (69%), prior CD19 CAR T cell therapy (38.4%),blinatumomab (61.5%), CD22-targeted therapy (38.4%), inotuzumab (30.7%), andCD22 CAR-T therapy (15.4%). Extramedullary disease was present in 46.2% ofpatients.

CAR Tcells were well tolerated and toxicities were reversible in all patients, DrShalabi said.

Cytokinerelease syndrome (CRS) developed in 46% of patients, 15.4% of which was grade 3or higher. Both patients who developed grade 3 or higher CRS had received the 1x 106 dose level of the CD19/CD22 CAR-T product and both requiredtreatment with tocilizumab. One patient developed neurotoxicity, and hadreceived the 3 x 106 dose level.

Of the12 patients evaluable for efficacy, a complete response (CR) was achieved by42% (5) of patients, including all patients who received the 1 x 106 or 3 x 106 dose levelsof the CD19/CD22 CAR-T therapy. There were 2 nonresponders.

Two patientswho received 1 x 106 CAR-T and all patients who received the 3 x 106dose level were negative for minimal residual disease (MRD), with the remainingCRs demonstrating bone marrow clearance. Four of the 5 patients who were MRDnegative were also naive to CAR-T therapy.

Of the 5patients who achieved a CR, 2 relapsed with CD19-positive/CD22-positive diseaseand 3 remained in remission at a median 7 months after CAR T cell infusion.

Severalpatients, however, who were MRD negative in the bone marrow did not achieve CRin their extramedullary disease. Dr Shalabi said that these discrepant resultsbetween marrow and extramedullary disease suggests potentially limited CAR-Ttrafficking to sites of extramedullary disease. She suggested that treatmentat higher dose levels may be needed to overcome this limitation.

CAR T-cellexpansion occurred in all patents who responded, with a median peak inperipheral blood of 7%. At day 28, there were 1.3% CAR T cells in the bonemarrow. The persistence of the CAR T cells in peripheral blood was a median of45.6 days, as measured by flow cytometry.

Dr Shalabi concluded that this early experience with bispecific CD19/CD22 CAR T cells demonstrates clinical activity with reversible CRS and limited neurotoxicity. She noted that future studies will explore a 1 x 107 dose level, intensification of lymphodepletion prior to CAR-T infusion, and consideration of the potential role of immune checkpoint inhibitors to augment CAR-T in extramedullary disease.

Read more of Cancer Therapy Advisors coverage of AACR 2020 meeting by visiting the conference page.

References

Shalabi H, Yates B, Shahani S, et al. Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL. Presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting I 2020; April 27-28, 2020. Abstract CT051.

See the article here:
Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL - Cancer Therapy Advisor

Bone Marrow Stem Cells Comments Off on Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL – Cancer Therapy Advisor | April 30th, 2020

NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2020, and provide a corporate update, at 8:30 a.m, Eastern Daylight Time, on Thursday, May 7, 2020.

BrainStorms CEO, Chaim Lebovits, will present a corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, President and Chief Medical Officer, David Setboun, PhD, MBA, Executive Vice President and Chief Operating Officer and Preetam Shah, PhD, MBA, Executive Vice President and Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. EDT, Tuesday, May 5, 2020.

Teleconference Details BRAINSTORM CELL THERAPEUTICS 1Q 2020

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors & Media" page of BrainStorm's website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

ABOUT NUROWNNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

ABOUT BRAINSTORM CELL THERAPEUTICS INC.:BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company's website.

SAFE HARBOR STATEMENT:Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTSInvestor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: + 1.862.397.1860pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

See the original post:
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT - BioSpace

Bone Marrow Stem Cells Comments Off on BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT – BioSpace | April 30th, 2020

Stem Cell Therapy market describes in-depth assessments and professional studies of the current and future status of the market worldwide, including valuable facts and figures. Stem Cell Therapy markets enhance this growth trend by providing information on new opportunities and market drivers, trends and future technologies. This report defines scope, coverage, production and CAGR (%) according to type, share, revenue status and outlook, capacity, consumption, market drivers, production status and outlook and opportunities, exports, imports, emerging market / national growth rates. This report provides a 360-degree overview of the industrys competitive environment. The Stem Cell Therapy market report evaluates key regions (countries) with a large market share during the forecast period.

Get sample copy of Stem Cell Therapy Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/691

The research in its endeavor to present an unbiased presentation of the Stem Cell Therapy market, complete with multi-faceted documentation of various market forces that collectively lend enormous growth impetus to the Stem Cell Therapy market. This report further reinforces vital statistical data on technological marvels that under prevailing circumstances direct growth in the Stem Cell Therapy market. A holistic understanding on PESTEL and SWOT analysis are also tagged in the report to unearth peculiarities of the Stem Cell Therapy market.

Full Browse the report description and TOC: https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Furthermore, Report provides the deep analysis about the impact of domestic and global players on market, trade regulation, value chain optimization, and opportunities analysis for new present as well as new players, recent developments, strategic market growth analysis, area marketplace expanding, product launches, technological innovations and many more. The study report of global Stem Cell Therapy market can be split on the basis of key segments such as product type, application, key companies and key regions. Also the growth of the global Stem Cell Therapy market can be projected on the basis of segments and calculation for sales by application and type of the product in terms of volume and value.

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

This market ready research offering on Stem Cell Therapy market is a go-to synopsis that highlights on all the core developments simultaneously dominant across all regional hubs in the Stem Cell Therapy market and their subsequent implications on holistic growth trajectory of Stem Cell Therapy market globally. The report is aimed at answering all the relevant queries pertaining to the target market based on which successful business decisions could be rapidly applied, favoring uncompromised growth in the Stem Cell Therapy market.

The report also lends light on competition spectrum, highlighting core market participants who are identified as frontline players in Stem Cell Therapy market as highlighted by this research. In its bid to equip players with real time understanding of the various operational factors dominant across regions, the research elaborating on Stem Cell Therapy market also houses crucial data on various geographical hubs identified in Stem Cell Therapys market as presented.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more from the original source:
Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Latest Herald

Bone Marrow Stem Cells Comments Off on Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 – Latest Herald | April 30th, 2020

VANCOUVER, Washington, April 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., President and Chief Executive Officer, and Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic services provider and an advisor to CytoDyn, will provide a comprehensive update on leronlimab for COVID-19. The Wall Street Reporter's event is scheduled for Friday, May 1, 2020 at 12:30 pm ET / 9:30 am PT.

Dr. Pourhassan will provide an update on patient enrollment in eIND, Phase 2 and Phase 2b/3 COVID-19 trials. Dr. Patterson will discuss his latest discovery of the mechanism of action of COVID-19 and the effect of leronlimab.

Interested participants are encouraged to login early prior to the start of the event, as the online event has a capacity of 3,000 participants and the Company's recent investment community conference call had over 3,600 participants. The livestream presentation will be archived for 30 days. For anyone unable to attend, a video will be posted on CytoDyn's website approximately 24 hours after the presentation. The conference sponsor provides corporate visibility services to CytoDyn for a fee.

About Coronavirus Disease 2019CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.

SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a "Fast Track" designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH.Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted "orphan drug" designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells.The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn completed the filing of its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Company's cash position, (ii)the Company's ability to raise additional capital to fund its operations, (iii) the Company's ability to meet its debt obligations, if any, (iv)the Company's ability to enter into partnership or licensing arrangements with third parties, (v)the Company's ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Company's ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Company's clinical trials, (viii)the results of the Company's clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company's products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Company's control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com

More here:
CytoDyn's Drs. Pourhassan and Patterson to Present Live at Wall Street Reporter's Event to Discuss Paper Recently Submitted for Publication and...

Bone Marrow Stem Cells Comments Off on CytoDyn’s Drs. Pourhassan and Patterson to Present Live at Wall Street Reporter’s Event to Discuss Paper Recently Submitted for Publication and… | April 30th, 2020

DURHAM, N.C., April 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the Companys initiation of a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI).

DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties, including the potential to address underlying causes of coagulation disorders with substantially reduced risk of bleeding complications compared to commercially available forms of heparin.1

Given the severity of the COVID-19 pandemic, we have evaluated many potential targets to address the clinical manifestations associated with severe COVID-19,said Joseph Lasky, M.D., Professor of Medicine, Pulmonary and Critical Care Section Chief, John W. Deming, M.D. Endowed Chair in Internal Medicine at Tulane University Medical School. Based on the literature, we believe DSTAT has the potential to reduce the excessive inflammation, immune cell infiltration and hypercoagulation associated with poor outcomes in patients with severe COVID-19 infection.

DSTAT is well-suited to unlock the anti-inflammatory properties of heparin as it may be dosed at much higher levels than any available form of heparin without triggering bleeding complications, said Mike Sherman, Chief Executive Officer of Chimerix. We had planned to evaluate DSTAT in several indications of high unmet need, including ALI from different causes. The pandemic intensified our focus on ALI associated with COVID-19. Our team has worked closely with critical care physicians treating COVID-19 patients and with the U.S. Food and Drug Administration (FDA) to develop a Phase 2/3 protocol to determine if DSTAT can reduce the need for mechanical ventilation and improve the rate of survival in patients with severe COVID-19 infection.

Phase 2/3 Study Design

The study is a 1:1 randomized, double-blind, placebo-controlled, Phase 2/3 trial to determine the safety and efficacy of DSTAT in adults with severe COVID-19 who are at high risk of respiratory failure. Eligible subjects will be those with confirmed COVID-19 who require hospitalization and supplemental oxygen therapy. The primary endpoint of the study is the proportion of subjects who survive and do not require mechanical ventilation through day 28. Additional endpoints include time to improvement as assessed by the National Institute of Allergy and Infectious Disease ordinal scale, time to hospital discharge, time to resolution of fever, number of ventilator-free days, all-cause mortality, and changes in key biomarkers (e.g. interleukin-6 (IL-6), tumor necrosis factor- (TNF-), high mobility group box 1 (HMGB1), C-reactive protein and d-dimer).

The Phase 2 portion of the study will enroll 24 subjects to confirm the maximum safe dose and will then expand by an additional 50 patients (74 total) at the selected dose. A formal analysis of all endpoints, including supportive biomarkers will be performed at the conclusion of the phase 2 portion of the study. Contingent upon positive results, the Phase 3 portion of the study will enroll approximately 450 subjects.

Clinical Rationale for DSTAT in COVID-19 Patients with ALI

The clinical manifestations of COVID-19 range from mild, self-limited respiratory tract illness to severe alveolar damage and progressive respiratory failure, multiple organ failure, and death. Mortality in COVID-19 is associated with severe pulmonary disease and coagulation disorders such as disseminated intravascular coagulation (DIC).2,3

The mechanistic rationale supporting DSTATs potential in ALI patients with COVID-19 is two-fold:

In a recent Phase 2 Acute Myeloid Leukemia (AML) study DSTAT was well tolerated with adverse events similar across DSTAT and control groups. DSTAT is an investigational agent, not yet licensed or approved for use.

Conference Call and Webcast

Chimerix will host a conference call and live audio webcast today at 8:30 a.m. ET. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 8263766.

A live audio webcast of the call will also be available on the Investors section of Chimerixs website, http://www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).

Dociparstat sodium is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity In vitro and in vivo animal model data support DSTATs potential to reduce the inflammation and cellular infiltration associated with acute lung injury and address coagulation disorders associated with COVID-19 pathology. Separately, DSTAT inhibits the activities of several key proteins implicated in the viability of AML blasts and leukemic stem cells in the bone marrow during chemotherapy (e.g., CXCL12, selectins, HMGB1, elastase). Randomized Phase 2 data suggest that DSTAT may also accelerate platelet recovery post-chemotherapy via inhibition of PF4, a negative regulator of platelet production that impairs platelet recovery following chemotherapy. BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For further information, please visit the Chimerix website, http://www.chimerix.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the mechanism of action of DSTAT and its potential in ALI patients with COVID-19; Chimerixs ability to develop DSTAT, including the initiation of a Phase 2/3 clinical trial for DSTAT as a potential treatment for ALI associated with COVID-19; and Chimerixs ability to submit and/or obtain regulatory approvals for DSTAT. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that DSTAT may not achieve the endpoints of the Phase 2/3 clinical trial; risks that DSTAT may not obtain regulatory approval from the FDA or such approval may be delayed or conditioned; risks that development activities related to DSTAT may not be completed on time or at all; Chimerixs reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACT:Investor Relations:Michelle LaSpaluto919 972-7115ir@chimerix.com

Will OConnorStern Investor Relationswill@sternir.com212-362-1200

Media:David SchullRusso Partners858-717-2310david.schull@russopartnersllc.com

note: DSTAT may be referred to as 2-O,3-O desulfated heparin, ODSH or CX-01 in these references.

Excerpt from:
Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19 - BioSpace

Bone Marrow Stem Cells Comments Off on Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19 – BioSpace | April 30th, 2020

A Co Armagh cancer survivor is inspiring people to Race for Life at Home and carry on the fight against the disease in these unprecedented times.

Clare Crossey (33), a care worker from Lurgan who was diagnosed with leukaemia in February 2018, had hoped to take part in Cancer Research UK's Race for Life in Belfast on Sunday, May 24.

Unfortunately the Belfast Race for Life is among events which organisers Cancer Research UK have postponed this spring and summer to protect the country's health during the coronavirus outbreak.

But as the nation's lockdown continues, undeterred women and men are already vowing to carry on and complete a Race for Life at Home challenge in their garden or their nearest green space.

Clare is unable to take up the challenge right now, as she is recovering from a bone marrow transplant, but is determined to lend her support and has recruited her sister Alison and daughters Meabh (8) and Lily (11) - who are limbering up with Joe Wicks on YouTube every morning.

The mum-of-two's life changed very suddenly in February 2018 when she was diagnosed with acute myeloid leukaemia, a cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells.

She has faced a tough battle for survival over the past two years and this time last year was in isolation receiving treatment and a stem cell transplant.

As she now faces isolation again to protect herself from coronavirus, Clare is remaining upbeat.

She says: "I now have a brand new immune system, almost like I have been reborn, so I need to have all the injections a new baby has.

"This places me at especially high risk from the coronavirus. It is frightening, but with the help of family, I am being very careful.

"We're all going to be spending a lot of time indoors this spring, so it feels good to take back some control and plan something positive to help me and to help people who are going through cancer right now.

"That's why I am happy to ask people to please join in the fun and still feel part of the Race for Life community."

Clare recalls how her life changed virtually overnight two years ago.

She had just finished night duty as a domiciliary care assistant when she started to feel very tired and unwell.

She then developed a rash on her chest and bruising on her legs.

Concerned, she looked up her symptoms and was alarmed to discover she could have leukaemia and immediately made an appointment with at the local health centre. A doctor felt that she was being over-anxious and she was sent home with details of the Samaritans helpline but within two days she was being told in hospital she was lucky to be alive.

Clare recalls: "I had a feeling in the back of my head that things weren't right.

"The doctor obviously did not agree with my suspicions as they gave me the number for the Samaritans, a prescription for beta blockers and told me to make an appointment for the following Tuesday for blood tests. This was on a Friday and Tuesday seemed so far away.

"As I left the surgery in tears, my younger daughter Meabh's school called me to say she had fallen and hit her head. That was the last thing I needed, but thankfully she was okay.

"I described my symptoms to my boss and we thought perhaps I just needed a week off work as I was over-tired.

"My mother was helping with the girls, who were just five and nine at the time, and she was completely dumbfounded to find me having a bath at 2.30am on the Saturday morning. I had thought perhaps the heat would help with the pains I was having."

After her bath Clare did fall asleep but was stunned when she woke to discover she had lost a whole day, sleeping for 24 hours straight.

She was further alarmed on waking to discover she had blood round her mouth as her gums were bleeding and she also found a huge bruise on her thigh, which was swollen.

She rang Craigavon hospital and was advised to come to A&E where blood tests were taken.

She recalls: "A short time after arriving at the hospital I was called to the yellow area and I knew from my job that was the admissions area. My bloods came back very quickly and when both a doctor and nurse came to talk to me, I just knew it was serious."

Clare was advised to go to the City Hospital right away and on arrival was met by a consultant and nurse who admitted her immediately and broke the news that she might have leukaemia.

Clare recalls: "I cried and the first stupid question I asked was, 'Am I going to lose my hair?' My thinking was that if I lost my hair the girls would know I was really ill, so I would have to tell them the truth."

Chemotherapy treatment started immediately and Clare was told that had she waited until the following Tuesday for blood tests, she may not have been alive. The cancer was 85% through her body and she was given around 16 hours to live.

She was offered a place on a Cancer Research UK trial called AML 19, which involved 10 days of chemo, day and night, from February 4 until the end of March.

She says: "I was in hospital for six to eight weeks at a time and sometimes didn't even see the kids. That was really difficult as they were so young, but my parents Margaret and Pat were a great help."

From February to September 2018, Clare had intense chemotherapy and tests showed her bone marrow was clear.

However, there was another blow in December when further tests revealed the leukaemia was back.

"I was devastated," said Clare. "I was readmitted to hospital on January 5 last year and remained there until March 7. I was allowed out for my daughter Lily's confirmation and we had a party before I went back into hospital that night."

Clare was forced to remain in quarantine in a stem cell room while receiving full body radiation and chemotherapy injections.

She needed a stem cell transplant to save her life. Her brother Darren and sister Alison - both musicians living in America at the time - had already been tested for stem cell transplant and Alison was relieved to be a 100% match.

On April 15 of last year, Clare went through her stem cell transplant.

Two weeks later she suffered a severe reaction and her body went into toxic shock.

She recalls: "I was told it was rare to have side effects but I had them all.

"My oesophagus was burned with the radiation and I couldn't walk or talk.

"I couldn't breathe and began vomiting blood. I woke up with an ICU team at my bedside that had to literally cut my clothes off due to swelling. I apparently had put on 4st in fluid due to the toxic shock. I remember asking, 'Am I going to die?'"

It was at this point an unusual encounter in the hospital changed things. A man visiting another patient with a religious relic from the saint Padre Pio enclosed in a frame asked if he could leave it with Clare, believing it might be something that would give her strength.

She decided that if she was to survive she had to be positive.

She says: "That was on May 2 and as I held the frame I was in tears, but next morning I got up and began physio, although I wasn't able to wear either shoes or slippers after gaining 4st in fluid due to toxic shock.

"I started to eat shortly after and nobody could believe it. I was discharged on May 15."

Today she feels indebted to her family and the staff at 10 North in Belfast City Hospital for their amazing care.

"I would also like to say a special thank-you to all my cousins and close friends for their love and support throughout my journey," she says. "My sister flew home from the US to be with me for the second round of treatment but my close friends, cousins and aunt Bernadette were with me the whole time."

And after everything she has been through, she is hoping to give something back by calling on people to support Cancer Research UK's Race for Life at Home event.

Last year Race for Life participants in Northern Ireland raised 98,646 to support vital research to develop gentler and more effective treatments for cancer.

Many of the scientists and researchers funded by Cancer Research UK are currently being redeployed to help in the fight against Covid-19, including assisting with testing.

By helping to beat coronavirus, the charity can lessen the impact it is having on the care of cancer patients.

Jean Walsh, Cancer Research UK's spokesperson for Northern Ireland, said: "At a time when it feels like everything is at a standstill, there is one thing that hasn't stopped - cancer.

"Our priority as a charity is ensuring that people affected by cancer are getting the support they need right now.

"But we are already getting people asking about doing Race for Life at Home because they don't want to see the charity lose out on vital funding. It's truly humbling to see the response.

"So, from their homes, we'd love for supporters to join us and Race for Life at Home in these challenging times. From a run or 5K walk around the garden to limbo in the living room, there is no wrong way to Race for Life at Home.

"With no entry fee, people might choose to twerk, limbo, star jump, squat, skip, dance, or come up with their own novel way of taking part and share it with friends. The message is very much that 'while we might be apart, we're doing this together'. There is no wrong way to get involved and join our community."

You can visit raceforlife.org and sign up free for ideas on how to create your own Race for Life at Home challenge.

And the Cancer Research UK Race for Life Facebook page will help people feel energised with weekly live workout sessions.

Organisers are also inviting participants to join the Race for Life at Home community by sharing photos and videos on social media using the hashtag #RaceForLifeAtHome.

Cancer Research UK was able to spend over 2m last year in Belfast on some of the UK's leading scientific and clinical research.

A new date for Race for Life Belfast has been set for Wednesday, October 7.

Participants who have already signed up for a Race for Life event which is now postponed will be contacted directly by the charity. Participants will be transferred to the new date but if they can't make it there is the option to request a refund or donate the entry fee to help fund cancer research.

Visit raceforlife.org or call 0300 123 0770. Join in and share with #RaceForLifeAtHome

Belfast Telegraph

Read more:
Co Armagh mum diagnosed with leukaemia and told that she had just 16 hours to live now inspiring people to sign up and do the Race for Life at Home in...

Bone Marrow Stem Cells Comments Off on Co Armagh mum diagnosed with leukaemia and told that she had just 16 hours to live now inspiring people to sign up and do the Race for Life at Home in… | April 28th, 2020

Central to a lot of scientific research into aging are tiny caps on the ends of our chromosomes called telomeres. These protective sequences of DNA grow a little shorter each time a cell divides, but by intervening in this process, researchers hope to one day regulate the process of aging and the ill health effects it can bring. A Harvard team is now offering an exciting pathway forward, discovering a set of small molecules capable of restoring telomere length in mice.

Telomeres can be thought of like the plastic tips on the end of our shoelaces, preventing the fraying of the DNA code of the genome and playing an important part in a healthy aging process. But each time a cell divides, they grow a little shorter. This sequence repeats over and over until the cell can no longer divide and dies.

This process is linked to aging and disease, including a rare genetic disease called dyskeratosis congenita (DC). This is caused by the premature aging of cells and is where the team focused its attention, hoping to offer alternatives to the current treatment that involves high-risk bone marrow transplants and which offers limited benefits.

One of the ways dyskeratosis congenita comes about is through genetic mutations that disrupt an enzyme called telomerase, which is key to maintaining the structural integrity of the telomere caps. For this reason, researchers have been working to target telomerase for decades, in hopes of finding ways to slow or even reverse the effects of aging and diseases like dyskeratosis congenita.

Once human telomerase was identified, there were lots of biotech startups, lots of investment, says Boston Childrens Hospitals Suneet Agarwal, senior investigator on the new study. But it didnt pan out. There are no drugs on the market, and companies have come and gone.

Agarwal has been studying the biology of telomerase for the past decade, and back in 2015 he and his team discovered a gene called PARN that plays a role in the action of the telomerase enzyme. This gene normally processes and stabilizes an important component of telomerase called TERC, but when it mutates, it results in less of the enzyme being produced and, in turn, the telomeres becoming shortened prematurely. For the new study, researchers screened more than 100,000 known chemicals in search of compounds that could preserve healthy function of PARN. This led them to a small handful that seemed capable of doing so by inhibiting an enzyme called PAPD5, which serves to unravel PARN and destabilize TERC.

We thought if we targeted PAPD5, we could protect TERC and restore the proper balance of telomerase, says Harvard Medical Schools Neha Nagpal, first author on the new paper. These chemicals were tested on stem cells in the lab, made from the cells of patients with dyskeratosis congenita.

Read the rest here:
Molecules identified that reverse cellular aging process - Daily Times

Bone Marrow Stem Cells Comments Off on Molecules identified that reverse cellular aging process – Daily Times | April 28th, 2020

GlobalStem Cell Therapy Market, delivering a must-read report for industry stakeholders wanting to understand the strategic landscape of this burgeoning sector. Readers will find an in-depth analysis of the market and how it will impact existing traditional markets, as well as insights into future development and opportunities across the globe.

MarketInsightsReports has announced the addition of the Global Stem Cell Therapy Market Research Report 2020 The report focuses on global major leading players with information such as company profiles, product picture and specification.

Get Sample Copy of Stem Cell Therapy Market Report

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/inquiry?Mode=10

Key Players:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix), request free sample for complete list of companies.

The leading players of industry, their market share, product portfolio, company profiles are covered in this report. The competitive market scenario among players will help the industry aspirants in planning their strategies.

Summary

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell Therapy market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Stem Cell Therapy industry.

Stem Cell Therapy Market Segmentation by types, Applications and regions:

Market Segment by Type covers:

Autologous

Allogeneic

Market Segmented by Applications:

Musculoskeletal Disorder

Wounds & Injuries

Cornea

Cardiovascular Diseases

Others

Market Segment by Regions:

North America (the United States, Canada, and Mexico)Europe (Germany, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)South America (Brazil, Argentina, Colombia, etc.)

Available [emailprotected] (Exclusive new year offer Flat 20%- Use code MIR 20):

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026/discount?Mode=10

These segments are thoroughly evaluated on an individual basis and a team of analysts has ensured to give a crystal clear idea about various lucrative segments of the industry. This detailed analysis using segmentation by providing precise results on industry-related markets.

The report also analyzed the evolution of industry trends. Several macroeconomic factors such as Gross domestic product (GDP) and the increasing inflation rate is expected to affect directly or indirectly in the development of the industry.

Frequently Asked Questions about global market:

Customization of the Report:This report can be customized as per your needs for additional data up to 3 companies or 3 countries or nearly 40 analyst hours.

Note:

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Visit complete report@

https://www.marketinsightsreports.com/reports/04252004873/covid-19-impact-on-global-stem-cell-therapy-market-size-status-and-forecast-2020-2026?Mode=10

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and Chinese and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Sales)

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

More here:
Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) - Jewish Life News

Bone Marrow Stem Cells Comments Off on Stem Cell Therapy Market Revenue, Demands and Gross Margin, Forecasts to 2026 (Based on 2020 COVID-19 Worldwide Spread) – Jewish Life News | April 28th, 2020

Naina Mishra

Tribune News Service

Chandigarh, April 28

Fifty per cent Covid-19 cases in the city are from two affected pockets Bapu Dham Colony and Sector 30-B.

Though the street lanes from where cases are being reported are being sealed in Sector 30-B, residents have reportedly been found violating the social distancing norms by crossing roofs or playing indoor games in gatherings. This has now prompted the UT Administration to install CCTV cameras to keep a vigil on the residents in these pockets.

A total of 16 cases have been reported from Bapu Dham Colony and 14 from Sector 30-B. Manoj Parida, UT Adviser, said the outbreak needed to be contained by focusing resources at Bapu Dham Colony in Sector 26 and Sector 30-B.

CCTV cameras will be installed and drones will be used to nail those violating the norms. The police will also patrol the area regularly by donning personal protective equipment, said Parida.

MC Joint Commissioner Anil Garg said: Residents are not following social distancing and curfew orders.

Devinder Singh Babla, councillor, said: We have prepared a team of volunteers in Sector 30 and we are sealing the areas ourselves. Those found violating the norms will be penalised.

Read the original:
Give child a healthy life, not thalassaemia - The Tribune

Bone Marrow Stem Cells Comments Off on Give child a healthy life, not thalassaemia – The Tribune | April 28th, 2020

Spinal Cord Trauma Treatment Market: Global Industry Analysis 2012 2016 and Forecast 2017 2025is the recent report of Persistence Market Research that throws light on the overall market scenario during the period of eight years, i.e. 2017-2025. According to this report, Globalspinal cord trauma treatment marketis expected to witness significant growth during the forecast period.

This growth is expected to be primarily driven by increasing incidence of spinal cord trauma, and increasing government support to reduce the burden of spinal cord injuries. Additionally, development of nerve cells growth therapy is expected to boost the market in near future.

Report Highlights:

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17353

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17353

The global market for spinal cord trauma treatment is is estimated to be valued at US$ 2,276.3 Mn in terms of value by the end of 2017. The global spinal cord trauma treatment market is expected to expand at a CAGR of 3.7% over the forecast period to reach a value of US$ 3,036.2 Mn by 2025end.

Global Spinal Cord Trauma Treatment Market: Trends

Global Spinal Cord Trauma Treatment Market: Forecast by End User

On the basis of end user, the global spinal cord trauma treatment market is segmented into hospitals and trauma centers. Hospitals segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period.

Hospitals and trauma centers segments are expected to approximately similar attractive index. Hospitals segment accounted for 53.2% value share in 2017 and is projected to account for 52.5% share by 2025 end.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17353

Global Spinal Cord Trauma Treatment Market: Forecast by Injury Type

On the basis of injury type, the global spinal cord trauma treatment market is segmented into complete spinal cord injuries and partial spinal cord injuries.

Partial spinal cord trauma treatment segment is expected to show better growth than the completed spinal cord treatment segment due to higher growth in the incidence rate of partial spinal cord trauma than the complete spinal cord trauma. With US$ 1,870.3 Mn market value in 2025, this segment is likely to expand at CAGR 3.8% throughout the projected period.

Global Spinal Cord Trauma Treatment Market: Forecast by Treatment Type

On the basis of treatment type, the global spinal cord trauma treatment market is segmented into corticosteroid, surgery, and spinal traction segments.

Surgery segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. Surgery segment is the most attractive segment, with attractiveness index of 2.6 over the forecast period.

Global Spinal Cord Trauma Treatment Market: Forecast by Region

This market is segmented into five regions such as North America, Latin America, Europe, APAC and MEA. Asia-Pacific account for the largest market share in the global spinal cord trauma treatment market.

Large patient population due to the high rate of road accidents and crime is making the Asia Pacific region most attractive market for spinal cord trauma treatment. On the other hand, MEA and Latin America is expected to be the least attractive market for spinal cord trauma treatment, with attractiveness index of 0.3 and 0.5 respectively over the forecast period.

Read more:
Adoption of Spinal Cord Trauma Treatment Market to Increase During the COVID-19 Period on back of Increased Consumer Demand - Jewish Life News

Spinal Cord Stem Cells Comments Off on Adoption of Spinal Cord Trauma Treatment Market to Increase During the COVID-19 Period on back of Increased Consumer Demand – Jewish Life News | April 28th, 2020

MOSCOW, 28 APR RIA Novosti. A new approach to the regeneration of organs that are unrivalled in price and efficiency, has been developed by scientists at the National research University MIET. They created the material, as explained by the authors, will allow to restore the cardiac tissue after a heart attack in just 2-4 months. Data published in the journal Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.

the Experts of national research UNIVERSITY MIET for the first time in the world, according to them, managed to find a way of chemical bonding of carbon nanotubes with molecules of the most common blood protein albumin. Outdoor their physical mechanism has allowed us to develop a new method of laser 3D printing of nanocomposites.

Under the action of the laser between the albumin and carbon nanotubes there is a strong covalent bond that allows you to print the design specified shape. Living cells, e.g., connective tissue or myocardium easy root on some of the frames (scaffold), making possible the efficient recovery of damaged tissues of the body, said the head of the laboratory of biomedical nanotechnology, Institute of biomedical systems, national research UNIVERSITY MIET Alexander Gerasimenko.

As explained by scientists, they created cardiac implants is 3-4 times cheaper than Russian and 6-8 times cheaper than their foreign counterparts, outperforming both those, and others on a number of parameters. Except scaffolds used in tissue engineering, the technology is also suitable for the production of biosensors, microfluidic systems, and even advanced drugs against cancer.

We are able to print the material close to the characteristics of cardiac tissue: it can be reduced along with the myocardium and has electrical conductivity, the flowing currents of the heart. Our method also allows you to adjust the porosity of the structures, providing penetration as living cells and sprouting of capillaries and nerve endings, explained Alexander Gerasimenko.

Before implantation scaffold populated printed living cells and some time to ripen. As noted by experts of national research UNIVERSITY MIET, a number of successful experiments have shown that it can be used, including stem cells that can turn into cells of that tissue into which they are transplanted.

Scientists believe that their method will effectively deal with such pathologies as congenital heart disease and myocardial infarction, aneurysm, atherosclerosis and infarction. According to them, nano-composite patch on myocardial infarction after 2-4 months completely restores the affected area, and the frame is thus resolved.

the Scientists noted that the technology is implemented in close cooperation with leading Russian scientific centers. In the future, the team intends to proceed to introduce the method into clinical practice, and to adapt the technology for creating coatings for various implantable systems.

More here:
In Russia figured out how to cure myocardial infarction in a matter of months - The KXAN 36 News

Cardiac Stem Cells Comments Off on In Russia figured out how to cure myocardial infarction in a matter of months – The KXAN 36 News | April 28th, 2020

By Guy Adams and John Naish Apr 25, 2020

Share this article:

London - Modern science has scarcely presented a more crucial goal, offering untold riches and perhaps even a Nobel prize to the victor, as well as the chance to return the world to normal.

Yet the search for a cure for coronavirus is also uniquely perilous thanks to the dangers inherent in rushing new medical products to market.

Across the globe, thousands of researchers employed by governments, laboratories and drug firms are working flat-out to crack this all-important riddle.

As are endless armchair experts, whose numbers now evidently include Donald Trump.

Yesterday, the worlds most powerful man used a press conference to propose various highly unorthodox new treatments for coronavirus, including injecting disinfectant into the body and blasting patients with ultraviolet light.

Back in the real world, researchers are working tirelessly to combat the virus.

But while bullish claims have been made for a host of possible treatments, the truth is that scientists have little idea which ones might end up being of use.

Four months into the pandemic, we have had millions of people infected but no data yet to show that any particular treatment is especially effective, says Professor Babak Javid, the Principal Investigator at Tsinghua University school of medicine in Beijing, and a consultant in infectious diseases at Cambridge University Hospitals.

Nonetheless, here are some of the most likely candidates.

In mid-March, the American President used Twitter to amplify reports that Covid-19 patients could be successfully treated via a combination of the malaria drug hydroxychloroquine and a common antibiotic, Azithromycin.

In a later press conference, the President insisted that common sense qualified him to make such a claim, urging Americans to take it and asking them: What have you got to lose?

Well, quite a lot, as it turned out. The drugs have a catalogue of nasty side-effects, including an increased risk of cardiac arrest, skin blistering, hearing loss and an inability to move the eyes.

A study this week of 368 male coronavirus patients found that 28 per cent of those treated via hydroxychloroquine alone and 22 per cent who received both drugs (the malaria treatment and azithromycin) in U.S. hospitals died. This compares to a death rate of just 11 per cent for patients who received standard care without either drug.

Hope and hype about the drug Remdesivir have set Californian biotech firm Gileads share price soaring in recent weeks.

The medicine, which is administered via a drip, was originally developed to fight the ebola virus and works by interfering with its genetic makeup.

Although other drugs were soon found to be more effective at treating ebola, subsequent tests suggested Remdesivir had some effect on respiratory viruses such as Sars and Mers. It also appears to be relatively safe.

Gilead has so far given Remdesivir to 1,700 coronavirus patients, with dramatic effects reported in some cases. Two major studies, in the U.S. and Europe, are currently underway.

Sadly, a full-scale clinical trial in China, which has been running for longer, found no evidence it improved the fate of hospital patients, according to documents accidentally leaked this week by the World Health Organisation.

Gilead responded that these leaks contained inappropriate characterisations and insisted their findings were inconclusive.

One reason that the Chinese trials outcome was so disappointing could be that Remdesivir is likely to work best if administered early.

With Covid-19, the virus mostly replicates soon after infection, says Professor Javid. If you give the anti-viral later in the course of an illness, when a patient is hospitalised, there is not much virus left for the drug to attack.

The golden goose for pharmaceutical firms is to discover a new antibody treatment that can attach to individual particles of coronavirus and stop them wreaking havoc.

Two US drug companies, Amgen and Adaptive, recently announced a partnership to study recovered Covid-19 patients in an effort to identify and manufacture crucial virus-killing antibodies.

Another firm, Regeneron, has been conducting a study using the viruss genetic material in mice. Dozens of other companies are pursuing similar projects.

Although an antibody strategy was used against ebola, most new drugs take more than five years to develop, thanks among other things to rigorous testing designed to ensure they do not have dangerous side-effects.

This fashionable, if highly experimental, field involves harvesting blood from people who have recently recovered from coronavirus and donating it to patients who are still suffering from the disease.

Because blood plasma contains antibodies that have learned how to detect and destroy the virus, the theory is that a transfusion will kick-start the recipients ability to fight it.

Its quite easy to harvest plasma from surviving patients, says Professor Javid. It was done even during the Spanish Flu epidemic of 1918-19.

About 600 patients in America have already received this treatment. The NHS is also said to be preparing to carry out an extensive trial in the UK.

However, some experts have pointed out that many Covid-19 victims die because of an overactive immune response to the virus, causing inflammation of lungs and other vital organs. These experts worry that boosting a patients immunity via plasma therapy could actually worsen their condition.

Another problem with plasma therapy is the old-fashioned issue of supply and demand. A limited number of recovered patients are prepared to give blood, and only a finite amount can be taken from them.

However, technology now exists to manufacture synthetic antibodies using the blood of Covid-19 survivors.

Such monoclonal antibodies have become the standard treatment for ebola. Several laboratories have identified monoclonal antibodies that can apparently inhibit coronavirus in test-tubes.

Professor Javid warns, however: No one has yet worked out which of the promising monoclonal antibodies work best for Covid-19, or what might be the best way to use them in combination. This is why they are not in production yet for Covid-19.

Contracting HIV was once a virtual death sentence, but after decades of research, its now mostly a highly manageable condition thanks to a raft of well-tolerated drugs.

Indeed, many HIV drugs are now being touted as possible treatments for coronavirus, including Lopinavir and Ritonavir.

These are being trialled on coronavirus patients in studies at the Universities of Oxford and Nebraska.

But so far there is little evidence of them working outside of a laboratory setting.

The so-called master cells that develop into blood, brain, bones and organs have been touted as the basis for cures for cancer, heart disease and arthritis for years.

Little wonder, then, that the pioneering field of stem cell therapy is now being targeted at coronavirus. Among firms exploring this modish area are Mesoblast, whose boffins are testing bone-marrow cells to establish whether they can help patients develop immunity to the virus. In Wuhan, meanwhile, doctor Dongcheng Wu last month claimed hed treated nine patients by injecting umbilical stem cells. He said they all made a complete recovery within days. The success has not yet been convincingly replicated, however. Stem cell treatments are often risky, too when trialled on Parkinsons, they caused brain tumours.

Around half the patients who die with coronavirus suffer a so-called cytokine storm, in which their immune system goes into overdrive, causing, among other things, acute lung inflammation that stops them from taking on enough oxygen. With this in mind, many products designed to combat inflammation are now being trialled on Covid patients.

They include Tocilizumab, used to treat rheumatoid arthritis, and Dexamethasone, a steroid used against asthma.

The World Health Organisations Solidarity trial is meanwhile testing interferon-beta, which is used to treat multiple sclerosis.

Professor Javid believes immune drugs should be accompanied by effective antiviral treatment: We know from treating flu patients suffering cytokine storms that if you dampen their immune response without also giving them an antiviral drug, it can reduce the patients virus-fighting defences and allow the virus to run wild.

These are the cholesterol-lowering drugs prescribed to millions at risk of heart disease. Now scientists wonder if statins should be given to patients with severe Covid-19 symptoms, for two reasons.

Harvard University investigators recommend their use because they have anti-inflammatory powers.

Scientists added last month in the journal Drug Development and Research that statins have also shown an ability to moderate the immune system and thus protect patients lungs from cytokine storm damage.

Professor Jon Cohen, emeritus professor of infectious diseases at Brighton and Sussex Medical School, argues that while statins have shown potential in test-tube trials, in living patients they have only really shown benefits for the cardiovascular system.

In normal circumstances viruses develop a key that enables them to pick a cells locks and break in, hijacking the cells machinery to make more copies of the virus. Peptide inhibitors stick to this key, rendering it unable to do its job.

We already know that Covid-19 invades human cells through a protein receptor, ACE2.

The big question, therefore, is: what might block the coronavirus attaching to the ACE2 receptor?

Chemists at Illinois University used high-powered computers to identify the amino-acid chemicals in the ACE2 receptor that the virus targets. They then constructed a drug with amino-acids that should stick to the viruss key, rendering it useless.

But as the scientists acknowledge in journal ACS Nano this month, they have tested their chemical in computer simulations not in the lab and certainly not on humans. A lot of hurdles lie ahead.

Ultimately, most scientists agree that coronavirus prevention a vaccine is better than any treatment or cure.

Thats why governments are throwing the proverbial kitchen sink at efforts to create one, with more than 140 projects currently running in parallel all over the world.

Everyone expects a vaccine to appear in the end. But much hinges on how quickly that happens.

Thats why there was so much excitement this week when it emerged that scientists at Oxford University have already begun to conduct their first human vaccine tests.

Other clinical trials in humans are already underway in China.

Nevertheless, Professor Chris Whitty, Englands Chief Medical Officer, says the chance of a vaccine becoming available in the next calendar year are incredibly small.

Why? Because we can move only as quickly as extreme caution will allow, says inoculation expert Dr Kai Hu of Imperial College. He reports Imperials lab has already created a harmless pseudo-virus that carries a coronavirus protein. But, he stresses: Safety is our number one priority. We dont yet know how toxic the vaccine would be to humans.

Given Covid-19s devastating infectiousness, the world will have to keep its fingers crossed that the dash for an effective jab proves a success rather than inadvertently plunging humanity into further peril.

Three members of the same family are taking part in a groundbreaking coronavirus vaccine trial. Mum Katie, dad Tony and daughter Rhiannon Vinney are among more than 1,000 participants taking part in the Oxford University trials.

Teaching assistant Katie, 46, saw the plea for healthy volunteers and urged her husband, 53, who runs two pubs, and their 18-year-old student daughter to sign up with her.

The mum-of-four, from Oxford, said she was not worried about health risks from taking part, because she believes the team have done everything they could to make it safe.

She added: I just want to help so life can return to normal. You have to live in a cave not to know somebody who is affected by this. I really do hope this is the cure.

Read this article:
Will the race for a Covid-19 cure end in triumph or tragedy? - IOL

Cardiac Stem Cells Comments Off on Will the race for a Covid-19 cure end in triumph or tragedy? – IOL | April 28th, 2020

By Sarah Parsons 28-Apr-2020

Hair Care | Ingredients | Skin Care

The Swiss-led speciality chemicals manufacturer Clariant Active Ingredients has developed two new plant-based ingredients

Speciality chemicals giant Clariant has unveiled its latest beauty ingredients.

This week, the Swiss-led company launched two new plant-based ingredients for skin and hair.

Clariant Active Ingredients, Clariant's beauty business unit, released Rootness Energize, an extract of Luffa cylindrica, otherwise known as Egyptian cucumber, and can also be used as a natural cleaning sponge.

Developed for the skin, Claraint claims that sustainably-sourced Rootness Energize is rich in bryonolic acid, and can increase energy production in skin cells and stimulate ATP production.

"In turn, Rootness Energize visibly increases skin elasticity and reduces age-related lack of tonicity and firmness appealing factors for products such as firming creams, skin elasticity boosters and revitalising care products for well-aging skin care," explained the company.

Reported visible results include more than a 20% increase in firmness, tonicity and elasticity with 1% Rootness Energize.

For the hair, Clariant Active Ingredients has developed EquiScalp to target tightness, extreme dryness, itchiness and redness.

Based on stem cells from the Central Asian Malus domestica apple tree, according to the firm, the ingredient protects the scalp as it maintains the level of healthy bacteria.

Malus domestica is said to contain concentrated phloridzin, which can control inflammation as well as sebum overproduction.

Clariant Active Ingredients recommends EquiScalp for oily scalp treatments, sensitive scalp formulas and scalp itch erasers.

Alexandre Lapeyre, Global Head of Marketing, Clariant Active Ingredients, described EquiScalp and Rootness Energize as examples of using technology to develop sustainable ingredients.

"We apply science to nature to create potent actives effective at addressing very specific beauty needs, each one underpinned by plant resources preservation, traceability, no exploitation of cultural land and ecological cultivation," Lapeyre said.

"In doing so, we help cosmetic formulators support consumers requests for scientifically-proven and sustainably-sourced plant derived ingredients.

Like this story? For the latest in ingredients, formulation, packaging and regulation subscribe to SPC Magazine, for more information click here.

The rest is here:
Clariant taps natural sponges and apple trees for new beauty ingredients - Cosmetics Business

Skin Stem Cells Comments Off on Clariant taps natural sponges and apple trees for new beauty ingredients – Cosmetics Business | April 28th, 2020

Although I live in New York City, many of my friends call Seoul, South Korea, home. Through our many FaceTimes, KakaoTalk messages, and visits, they've introduced me to trendy Korean beauty brands that haven't made their way to America yet, like Hince, Sioris, and Nonfiction. They also share their picks from K-beauty brands we know and love in the U.S., such as Sulwhasoo, Dr. Jart, and Nature Republic. Every time I hear about their favorite products, I'm fascinated by how different they are from our stateside K-beauty offerings.

We're only exposed to a fraction of what is available on the other side of the world, and we are missing out on dreamy lip tints, barely-there cushion foundations, and magical moisturizers. With this in mind, I put my friends' makeup, hair, and skin-care selections in one place.

Some background on the names I'm about to mention: Daniella is my clean beauty expert. Whenever I see her, she always gives me a bag full of goodies made with natural, cruelty-free ingredients. When I want to know about the hottest brands at the moment, I go to Haylie. Joyce, founder of consulting agency Talk to Her, always has her eye out for the latest K-beauty innovations. Tattoo artist Young, on the other hand, mixes classic imports, like SK-II and Urban Decay, with unexpected K-beauty finds.

Consider this a list of K-beauty products Koreans actually use.

All products featured on Allure are independently selected by our editors. However, when you buy something through our retail links, we may earn an affiliate commission.

See the rest here:
23 Best Korean Beauty Products, According to Koreans Hair, Makeup, Skin-Care Reviews - Allure Magazine

Skin Stem Cells Comments Off on 23 Best Korean Beauty Products, According to Koreans Hair, Makeup, Skin-Care Reviews – Allure Magazine | April 28th, 2020